Which blood thinner combo best prevents a second stroke?
NCT ID NCT06591338
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial compares two anti-clotting drug combinations—aspirin plus ticagrelor versus aspirin plus clopidogrel—in 900 adults who recently had a minor stroke or transient ischemic attack (TIA) caused by a large artery blockage. Participants receive the drugs within 24 hours of their event and are followed for 90 days to see which combination better prevents new strokes, heart attacks, or death, while also tracking bleeding side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin plus ticagrelor or clopidogrel
What this could lead to
If successful, this could show that aspirin plus ticagrelor is better than aspirin plus clopidogrel at preventing another stroke after a minor stroke or TIA.
What could go wrong
This is a single-center trial in Egypt, so results may not apply worldwide. Both drug combinations increase bleeding risk, and the study is still recruiting, so final results are years away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kafr Elsheikh University Hospital
RECRUITINGKafr ash Shaykh, 33511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••